SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints

Kardiol Pol. 2022;80(2):198-201. doi: 10.33963/KP.a2021.0172. Epub 2021 Dec 6.

Josip A Borovac^{1

2}, Tina Kurir^{3

4}, Ivona Mustapic⁵, Marko Kumric³, Josko Bozic³, Duska Glavas⁵, Domenico D'Amario⁶

¹ Department of Pathophysiology, School of Medicine, University of Split, Split, Croatia. jborovac@mefst.hr.
² Clinic for Heart and Vascular Diseases, University Hospital of Split, Split, Croatia. jborovac@mefst.hr.
³ Department of Pathophysiology, School of Medicine, University of Split, Split, Croatia.
⁴ Department of Endocrinology and Diabetology, University Hospital of Split, Split, Croatia.
⁵ Clinic for Heart and Vascular Diseases, University Hospital of Split, Split, Croatia.
⁶ Department of Cardiovascular and Thoracic Sciences, IRCCS Fondazione Policlinico A Gemelli, Universita Cattolica Sacro Cuore, Rome, Italy.

No abstract available

Publication types